4.7 Article

Clinical outcome in IL-10-and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 131, Issue 3, Pages 825-+

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2012.09.025

Keywords

IL-10; IL-10 receptor; enterocolitis; mutations; colectomy; hematopoietic stem cell transplantation

Funding

  1. NEOPICS
  2. Canadian National Early Onset Pediatric Cohort Study
  3. European Commission Marie Curie Excellence program [MEXT-CT-2006-042316]
  4. EURO-PADNet
  5. Marie Curie Actions CIG [294253]
  6. USA National Institutes of Health/NCRR UCSF-CTSI [UL1 RR024131]
  7. UCSF Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies
  8. German Federal Ministry of Education and Research [BMBF 01 EO0803]
  9. Care-for-Rare Foundation
  10. National Institutes of Health
  11. European Community 6th Programme
  12. European Community 7th Programme
  13. Marie Curie Excellence grant
  14. German Federal Ministry of Education and Research
  15. European Commission/Marie-Curie Actions
  16. Great Ormond Street Hospital Childrens Charity [V1204] Funding Source: researchfish

Ask authors/readers for more resources

Background: Inherited deficiencies of IL-10 or IL-10 receptor (IL-10R) lead to immune dysregulation with life-threatening early-onset enterocolitis. Objectives: We sought to gather clinical data of IL-10/IL-10R-deficient patients and devise guidelines for diagnosis and management, including hematopoietic stem cell transplantation (HSCT). Methods: We enrolled 40 patients with early-onset enterocolitis and screened for mutations in IL10/IL10R using genetic studies, functional studies, or both of the IL-10 signaling pathway. Medical records of IL-10/IL-10R-deficient patients were reviewed and compiled. Results: Of 40 patients, we identified 7 with novel mutations, predominantly in consanguineous families with more than 1 affected member. IL-10/IL-10R-deficient patients had intractable enterocolitis, perianal disease, and fistula formation. HSCT was carried out in 2 patients with IL-10 deficiency and 1 patient with IL-10R a chain deficiency and proved to be an effective therapy, leading to rapid improvement of clinical symptoms and quality of life. Conclusion: Because the defect in patients with IL-10/IL-10R deficiency resides in hematopoietic lineage cells and their colitis is resistant to standard immunosuppressive therapy, HSCT should be considered early as a potentially curative therapeutic option. (J Allergy Clin Immunol 2013; 131:825-30.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available